NDATOPICALOINTMENT
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
2
Data completeness
5/8 — Partial
VEREGEN (sinecatechins) by ANI Pharmaceuticals is unknown. First approved in 2006.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEREGEN (sinecatechins) is a topical ointment derived from green tea extract approved in 2006 for external genital warts. The mechanism of action remains unclear, though in vitro studies suggest anti-oxidative activity with unknown clinical significance. It represents a botanical-derived therapeutic approach to a viral skin condition.
$0.235MPart D
LOE Approaching0mo to LOEMinimal market presence with only $235K in Part D spending signals a niche product in advanced lifecycle decline, requiring highly specialized sales and marketing teams.
Mechanism of Action
unknown. In vitro, sinecatechins had anti-oxidative activity; the clinical significance of this finding is unknown.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers
Started Dec 2011
30 enrolled
Anogenital Warts
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
Started Jan 2010
43 enrolled
Genital WartsPerianal Warts
Why This Matters for Your Career
Worked on VEREGEN at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.